€502.60
0.63% yesterday
Brüssel, Jun 13, 05:35 pm CET
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

arGEN-X Stock price

€502.60
+13.90 2.84% 1M
-78.20 13.46% 6M
-97.40 16.23% YTD
+144.00 40.16% 1Y
+308.70 159.21% 5Y
+490.31 3,989.50% 10Y
+494.70 6,262.03% 20Y
Brüssel, Closing price Fri, Jun 13 2025
-3.20 0.63%
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization €30.92b
P/E (TTM) P/E ratio 36.18
P/S ratio (TTM) P/S ratio 13.89
Revenue (TTM) Revenue €2.23b
EBIT (operating result TTM) EBIT €188.58m
EPS (TTM) EPS €14.03
P/E forward 45.32
P/S forward 9.59

Is arGEN-X a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

arGEN-X Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a arGEN-X forecast:

29x Buy
91%
3x Hold
9%

Analyst Opinions

32 Analysts have issued a arGEN-X forecast:

Buy
91%
Hold
9%

Financial data from arGEN-X

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,234 2,234
-
100%
- Direct Costs 229 229
-
10%
1,636 1,636
-
73%
- Selling and Administrative Expenses 949 949
-
42%
- Research and Development Expense 729 729
-
33%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 189 189
-
8%
Net Profit 921 921
-
41%

In millions EUR.

Don't miss a Thing! We will send you all news about arGEN-X directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today